2 weeks Ago By ABMN Staff
Fiera Capital Corp reduced its stake in Johnson & Johnson ( NYSE:JNJ – Free Report ) by 23.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,307,131 shares of the company’s stock after selling 992,930 shares during the quarter.
Johnson & Johnson makes up 1.5% of Fiera Capital Corp’s investment portfolio, making the stock its 20th largest holding. Fiera Capital Corp’s holdings in Johnson & Johnson were worth $483,370,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. lifted its stake in shares of Johnson & Johnson by 3.
3% in the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after buying an additional 288 shares during the period.
9258 Wealth Management LLC increased its position in shares of Johnson & Johnson by 2.1% during the fourth quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock valued at $3,454,000 after purchasing an additional 443 shares during the period.
Eagle Asset Management Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at $1,446,000. HFR Wealth Management LLC lifted its position in Johnson & Johnson by 2.
2% in the fourth quarter. HFR Wealth Management LLC now owns 51,467 shares of the company’s stock worth $8,067,000 after purchasing an additional 1,095 shares during the period. Finally, Poehling Capital Management INC.
boosted its stake in Johnson & Johnson by 11.5% during the fourth quarter. Poehling Capital Management INC.
now owns 3,074 shares of the company’s stock worth $482,000 after buying an additional 318 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Wall Street Analyst Weigh In JNJ has been the subject of several recent analyst reports. Morgan Stanley increased their price objective on Johnson & Johnson from $167.00 to $169.
00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $161.
00 to $171.00 in a research report on Thursday, July 18th. The Goldman Sachs Group cut their target price on shares of Johnson & Johnson from $160.
00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. StockNews.
com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $160.00 to $150.
00 in a research note on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.
21. Insider Buying and Selling at Johnson & Johnson In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th.
The shares were sold at an average price of $165.06, for a total transaction of $930,113.10.
Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website .
Corporate insiders own 0.16% of the company’s stock. Johnson & Johnson Price Performance Shares of JNJ opened at $161.
40 on Monday. The stock has a market cap of $388.44 billion, a PE ratio of 10.
06, a PEG ratio of 2.69 and a beta of 0.53.
The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.
44. The business has a 50-day simple moving average of $162.15 and a two-hundred day simple moving average of $154.
16. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.
85. Johnson & Johnson ( NYSE:JNJ – Get Free Report ) last posted its earnings results on Wednesday, July 17th. The company reported $2.
82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11.
The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion.
Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%.
The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.
80 EPS. Analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a dividend of $1.24 per share.
This represents a $4.96 annualized dividend and a yield of 3.07%.
The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is presently 30.92%.
Johnson & Johnson Profile ( Free Report ) Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. See Also Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ). Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter .
.
